5889DC37-2B83-4FA7-926E-EA69556FB769
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 50.09855453350854
- age_years
- 41
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.450
- TGF_BETA_SIGNALING+0.399
- G2M_CHECKPOINT+0.386
- PROTEIN_SECRETION+0.377
- E2F_TARGETS+0.369
- WNT_BETA_CATENIN_SIGNALING+0.366
- INTERFERON_ALPHA_RESPONSE+0.352
- HEDGEHOG_SIGNALING+0.331
- ADIPOGENESIS+0.324
- CHOLESTEROL_HOMEOSTASIS+0.317
Top 10 suppressed
- KRAS_SIGNALING_DN-0.262
- SPERMATOGENESIS-0.211
- MYOGENESIS-0.124
- APICAL_JUNCTION-0.019
- PANCREAS_BETA_CELLS-0.013
- ESTROGEN_RESPONSE_LATE+0.044
- ANGIOGENESIS+0.057
- OXIDATIVE_PHOSPHORYLATION+0.067
- INFLAMMATORY_RESPONSE+0.078
- COAGULATION+0.088
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ED604501-C110-4693-820B-DE9FB648FEAA | — | — | 0.912 |
| 2 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.906 |
| 3 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.902 |
| 4 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.900 |
| 5 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.899 |
| 6 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.896 |
| 7 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.896 |
| 8 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.894 |
| 9 | 8D30F824-25B9-43DB-BD39-2C9C790509DD | — | — | 0.893 |
| 10 | 01169BCB-82ED-4492-9FD0-630CCEA70023 | — | — | 0.890 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.399 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.386 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.377 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.369 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.366 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.352 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.331 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.324 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.317 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.307 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.306 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.305 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.305 | Inavolisib | — uncovered |
| APOPTOSIS | 0.295 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.281 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.245 | Inavolisib | — uncovered |